Osama Hassan

Osama Hassan

Auto-generated profile, based on publicly available information

Osama Hassan

Department of Psychiatry, Central and North West London NHS Foundation Trust, London, United Kingdom

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2025 in Inflammopharmacology
Verified
Journal Article
Open access
PDF file
NFNourAllah Farag
NourAllah Farag
ASAbdullah Selim
Abdullah Selim
OHOsama Hassan
Osama Hassan
HMHamdy A. Makhlouf
Hamdy A. Makhlouf
MSMahmoud Soliman
Mahmoud Soliman
OKOmar Kassar
Omar Kassar
Background: The hypothesis of immune and inflammatory dysregulation has been supported in the pathogenesis of schizophrenia; this systematic review and meta-analysis aims to evaluate the efficacy and safety of celecoxib, which is a COX-2 inhibitor with anti-inflammatory effects, in the management of schizophrenia. Methods: A comprehensive search of electronic databases, including PubMed, Scopus, Cochrane, and Web of Science, was performed in February 2025. We included only randomized controlled trials (RCTs) comparing celecoxib alone or as an adjunct to antipsychotics to placebo. Risk of bias was assessed using the ROB-2 tool, and the data of included studies were extracted and analyzed using RevMan 5.4 software. The primary outcome was the change in PANSS (Positive and Negative Syndrome Scale) total score. Results: Seven RCT studies comprising 438 patients with schizophrenia were included in this study. The risk of bias was low in most of the included studies. Celecoxib showed statistically significant improvement in PANSS total score (MD = − 8.45, 95% CI [− 13.62, -3.28], p value = 0.001), PANSS-positive scale (MD = − 3.34, 95% CI [− 4.67, − 2.02], P < 0.00001), PANSS-negative sub-scales (MD = − 2.47, 95% CI [− 3.75, − 1.19], P = 0.00002), and general psychopathology (MD = − 4.47, 95% CI [8.10, − 0.85], P = 0.02). No publication bias was detected based on the DOI plot. Conclusion: This study’s findings provide insights into the potential anti-inflammatory benefits of celecoxib in schizophrenia treatment. However, study limitations warrant cautious interpretation, highlighting the need for larger, well-designed trials to identify patient subgroups that may benefit most from this approach.

3 November 2025 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
OKOmar Kassar
Omar Kassar
MMMohamed Ezzat M. Mansour
Mohamed Ezzat M. Mansour
NFNourAllah Farag
NourAllah Farag
ASAbdullah Selim
Abdullah Selim
YKYasser Kewiaa
Yasser Kewiaa
OHOsama Hassan
Osama Hassan
Sulforaphane, an isothiocyanate derived from cruciferous vegetables (e.g., broccoli sprouts), has been explored for its antioxidant and anti-inflammatory properties. This is the first systematic review and meta-analysis to explore the therapeutic potentials of sulforaphane in schizophrenia. We searched PubMed, Scopus, Web of Science, and Cochrane Central for studies from inception to April 2025. We included randomized controlled trials (RCTs) evaluating the efficacy of sulforaphane in schizophrenia. The primary outcomes were changes in the Positive and Negative Syndrome Scale (PANSS) total and its subscales. Secondary outcomes included cognitive measures, metabolic markers, and safety. Four RCTs with 369 schizophrenia patients were included. Sulforaphane did not significantly improve PANSS total or positive symptom scores at the latest follow-up (ranging from 24 weeks to 18 weeks) or at a consistent 12-week time point. However, a modest improvement in negative symptoms was found at 12 week- time point (MD= -1.06; 95% CI: -1.95 to -0.16; p = 0.02), which was not maintained at the latest follow-up. General psychopathology scores improved significantly (MD= -1.5; 95% CI: -2.78 to -0.23; p = 0.02). No cognitive benefits were observed. Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol. Discontinuation rates were lower in the sulforaphane group (RR = 0.68; 95% CI: 0.49 to 0.95; p = 0.02). The study provides initial insights into sulforaphane’s potential therapeutic effects in schizophrenia, showing modest improvements in general psychopathology and negative symptoms, with favorable metabolic changes and lower discontinuation rates. Due to limited data and heterogeneity, the study findings should be interpreted with caution. Not applicable.

29 December 2025 in Asian Journal of Psychiatry
Verified
Journal Article
Closed access
OKOmar Kassar
Omar Kassar
ASAbdullah Selim
Abdullah Selim
SIShrabon Insan
Shrabon Insan
OHOsama Hassan
Osama Hassan
ASAlexander Sartorius
Alexander Sartorius

12 November 2026 in Child Psychiatry & Human Development
Verified
Journal Article
Closed access
OHOsama Hassan
Osama Hassan
OKOmar Kassar
Omar Kassar
AEAmr Abdullah Emirah
Amr Abdullah Emirah
HSHelen Simmons
Helen Simmons

5 November 2025 in General Hospital Psychiatry
Verified
Journal Article
Closed access
OHOsama Hassan
Osama Hassan
ASAbdullah Selim
Abdullah Selim
OKOmar Kassar
Omar Kassar